Testing a new drug DCR-PDL1 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called DCR-PDL1 for people with advanced solid tumors or non-Hodgkin's lymphoma that has not responded to, progressed on, or could not tolerate standard treatments, or for which no standard treatment exists. The goal is to see if it is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of advanced solid tumor or non-Hodgkin's lymphoma that has not responded to standard treatment, has gotten worse during or after standard treatment, you could not tolerate standard treatment, or no standard treatment is available.
- Your cancer must be measurable on scans and cannot be treated with surgery.
- You should have a life expectancy of at least 3 months and be able to care for yourself (ECOG 0-2).
- You must not have untreated or uncontrolled brain or spinal cord spread of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.